esc 2022: perspective: sacubitril/valsartan & cognitive function in hfmref & hfpef
Published 2 years ago • 1.9K plays • Length 5:52Download video MP4
Download video MP3
Similar videos
-
2:42
sacubitril/valsartan and frailty in hfpef in paragon-hf | esc congress 2022
-
7:42
hfsa 2022: prove-hf: effect of sacubitril/valsartan in hfref pts with mr | dr james l januzzi
-
7:57
hfa 2020: eligibility for sacubitril/valsartan in hf across the ef spectrum — dr gianluigi savarese
-
11:45
esc guidelines: managing hfmref (english version)
-
11:28
esc 2022 late-breaker discussion: the deliver trial
-
17:14
esc 2022 late-breaker discussion: the invictus trial
-
5:02
esc 2022: emperor-preserved & deliver meta-analysis: sglt2is in heart failure | dr vaduganathan
-
2:30
esc 2022: the all-heart trial: allopurionol in the treatment of ischaemic heart disease
-
8:20
hfa 2018: champ-hf -sacubitril/valsartan initiation in hf - dr yevgeniy khariton
-
53:46
a to z of cv pharmacotherapy | valsartan sacubitril: has our paradigm shifted?
-
4:45
esc 2022: the emperor-pooled trial: clinical benefits of sglt2i in heart failure | dr faiez zannad
-
7:03
esc 2022: 3 trials that will change your practice with preventive cardiologist, dr martha gulati
-
4:06
hf 2022: 2022 heart failure highlights with dr mikhail kosiborod
-
3:19
acc 22: results from the pacific af trial | dr manesh patel
-
11:06
esc 22 late-breaker discussion: the advor trial
-
7:26
esc 2022: the momentum 3 study: 5-year results from heartmate 3 lvad therapy | dr mandeep mehra
-
5:00
esc 22: panther: p2y12i vs aspirin monotherapy in pts with cad with prof valgimigli